Compare · JNJ vs MYNZ
JNJ vs MYNZ
Side-by-side comparison of Johnson & Johnson (JNJ) and Mainz Biomed N.V. (MYNZ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and MYNZ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $542.44B, about 2904.6x MYNZ ($186.8M).
- Over the past year, JNJ is up 45.1% and MYNZ is down 77.4% - JNJ leads by 122.5 points.
- JNJ has hit the wire 26 times in the past 4 weeks while MYNZ has been quiet.
- JNJ has more recent analyst coverage (25 ratings vs 4 for MYNZ).
- Company
- Johnson & Johnson
- Mainz Biomed N.V.
- Price
- $225.28-0.96%
- $0.83+0.48%
- Market cap
- $542.44B
- $186.8M
- 1M return
- -5.87%
- +1.47%
- 1Y return
- +45.08%
- -77.45%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 26
- 0
- Recent ratings
- 25
- 4
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Mainz Biomed N.V.
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic tests for clinical diagnostics in the area of human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, an early-stage molecular lateral-flow test; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Latest JNJ
- SEC Form 4 filed by Director Woods Eugene A.
- SEC Form 4 filed by Director West Nadja
- SEC Form 4 filed by Director Weinberger Mark A
- SEC Form 4 filed by Director Pinto Daniel E
- SEC Form 4 filed by Director Morikis John G
- SEC Form 4 filed by Director Mcclellan Mark B.
- SEC Form 4 filed by Director Joly Hubert
- SEC Form 4 filed by Director Johnson Paula A
- SEC Form 4 filed by Director Hewson Marillyn A
- SEC Form 4 filed by Director Doudna Jennifer A
Latest MYNZ
- SEC Form PRE 14A filed by Mainz Biomed N.V.
- Mainz Biomed N.V. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors
- SEC Form 4 filed by Director Lazar David E.
- New insider Lazar David E. claimed no ownership of stock in the company (SEC Form 3)
- Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples
- Chief Financial Officer Caragol William J was granted 290,000 units of Ordinary Shares, increasing direct ownership by 372% to 367,899 units (SEC Form 4)
- Director Dreismann Heinrich was granted 45,000 units of Ordinary Shares, increasing direct ownership by 228% to 64,700 units (SEC Form 4)
- Director Tibbitts Gregory J was granted 45,000 units of Ordinary Shares, increasing direct ownership by 414% to 55,875 units (SEC Form 4)
- Chief Executive Officer Baechler Guido was granted 440,000 units of Ordinary Shares, increasing direct ownership by 267% to 605,058 units (SEC Form 4)